The implications of the latest evidence for TAVI in daily practice
This video is supported by an unrestricted grant provided by Edwards Lifesciences
Summary
Join Hélène Eltchaninoff and Hendrik Treede as they talk to Bernard Prendergast about the impact of the latest evidence from the field of TAVI on everyday clinical practice. 2019 has been a landmark year for valve disease, with the results of the PARTNER 3 trial and the Evolut Low Risk trial marking a pivotal moment in the evolution of transcatheter valve technologies. What effect will these results have on the treatment of patients with symptomatic severe aortic stenosis? And what will be the focus of future research in TAVI?
This roundtable supported by an unrestricted grant by Edwards Lifesciences was filmed at EuroPCR 2019: see more videos here